Company Filing History:
2 out of 375 
2 out of 13 
1 out of 4,920 
Years Active: 2008-2009
Title: Miki Ohira: Innovator in Neuroblastoma Prognosis
Introduction
Miki Ohira is a notable inventor based in Chiba, Japan, recognized for his contributions to the field of medical diagnostics, particularly in neuroblastoma prognosis. With a total of 2 patents, his work has significant implications for improving patient outcomes in this challenging area of oncology.
Latest Patents
Ohira's latest patents include a microarray designed for predicting the prognosis of neuroblastoma. This microarray features 25 to 45 probes related to good prognosis, which are hybridized to gene transcripts whose expression is increased in patients with favorable outcomes. Additionally, it includes probes related to poor prognosis, allowing for a comprehensive assessment of the disease. Another significant patent involves a diagnostic agent or kit that utilizes nucleic acids isolated from stage 4 neuroblastoma, aimed at classifying the disease's progress and determining the specific stage of neuroblastoma.
Career Highlights
Throughout his career, Miki Ohira has worked with prominent organizations, including Hisamitsu Pharmaceutical Company, Inc. and the Chiba-prefecture. His experience in these institutions has contributed to his expertise in developing innovative solutions for medical diagnostics.
Collaborations
Ohira has collaborated with notable colleagues such as Akira Nakagawara and Shin Ishii, enhancing the impact of his research through teamwork and shared knowledge.
Conclusion
Miki Ohira's innovative work in neuroblastoma prognosis exemplifies the critical role of inventors in advancing medical science. His contributions continue to pave the way for improved diagnostic methods and patient care.